Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN

This trial is a multicenter, prospective, single-arm exploratory clinical study to evaluate the efficacy and safety of Penpulimab injection combined with cetuximab in the first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.

Trial Details

NCT ID

NCT05260671

Phase

PHASE2

Sponsor

Eye & ENT Hospital of Fudan University

Status

RECRUITING

Cancer Type

Head and Neck Cancer

Interventions

Penpulimab combined with cetuximab

Locations (sample)

Changchun, Jilin, China|43.88,125.32278
Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

Age: ≥ 18 years, male or female;
Histologically confirmed squamous cell carcinoma of the head and neck (oral cavity, oropharynx, larynx, hypopharynx) (SCCHN);
Recurrent/metastatic SCCHN not suitable for local treatment such as surgery or radiotherapy in the opinion of the investigator;
At least one measurable tumor lesion according to RECIST 1.1 criteria;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →